NPPA Uses Pharma Sahi Daam App to Track Drug Price Violations, Parliament Informed
New Delhi: Drug price violations are also tracked through NPPA's Pharma Sahi Daam mobile app, allowing consumers to check prices and lodge complaints, bringing citizen-led oversight into pharmaceutical price regulation, the Parliament was informed.
Raising the issue in the Lok Sabha, MP Tatkare Sunil Dattatrey sought details on how the Government ensures effective monitoring of compliance with pharmaceutical rules, the types of sectoral data being tracked, and whether plans exist to establish a unified data-monitoring body for better policy intervention.
Responding to the query, the Minister of State in the Ministry of Chemicals and Fertilizers, Anupriya Patel stated that drug price regulation is governed by the National Pharmaceuticals Pricing Policy (NPPP), 2012, implemented through the Drugs (Prices Control) Order, 2013 (DPCO, 2013) by the National Pharmaceutical Pricing Authority (NPPA).
Commenting on the steps being taken by the Government to ensure efficient monitoring and evaluation regarding compliance with pharmaceutical rules and regulations in the country, the Minister informed that in accordance with the provisions of DPCO, 2013, NPPA fixes ceiling prices of scheduled formulations, i.e., medicines included in the National List of Essential Medicines (NLEM) issued by the Ministry of Health and Family Welfare and incorporated in Schedule-I to DPCO, 2013.
NPPA also fixes retail prices of new drugs as defined in DPCO, 2013. Further, in case of non-scheduled formulations, manufacturers are not permitted to increase the maximum retail price (MRP) of such formulations by more than 10% of MRP over a period of the preceding 12 months.
In addition, every manufacturer is required to issue a price list and supplementary price list in the specified form to dealers, State Drugs Controllers, and the Government, indicating reference to prices fixed or revised as aforesaid from time to time.
NPPA monitors compliance with DPCO, 2013 based on the references received from the Price Monitoring and Resource Units set up in States, State Drugs Controllers, NPPA’s Pharma Sahi Daam app, samples purchased from the open market, reports from market database, and complaints lodged through various grievance redress channels.
"Appropriate action is initiated against drugs manufacturers for any violations after examination, in accordance with the provisions of DPCO, 2013." the Minister added.
It was further informed that regulatory control over manufacturing, sale and distribution of drugs is exercised through a system of licensing and inspection by State Licensing Authorities (SLAs) appointed by State Governments, while regulatory control over drugs imported into the country is exercised by the Central Government through the Central Drugs Standard Control Organisation (CDSCO).
She further added, "Drug inspectors are required to inspect the facilities licensed under the Act from time to time, with a view to verify compliance with the provisions of the Drugs and Cosmetics Act, 1940 and the rules made thereunder. Further, joint inspections of licensees are carried out by the drug inspectors of CDSCO and States on a risk-based approach."
Outlining the details of the data streams from the pharmaceutical sector (such as pricing, sales, prescription, research, etc.) that are combined and monitored by the Government, the Minister informed, "NPPA utilizes market-based data such as pricing, sales, quantity, moving average turnover etc. provided by a third-party agency. It analyzes and monitors the data to perform its core functions of fixation of ceiling/retail price, monitoring, overcharging assessment and overall market surveillance under DPCO, 2013."
On the query regarding whether there are any plans to set up a unified body dedicated to monitoring and analyzing data from the pharmaceutical sector to better guide policy making and intervention, and if so, the details thereof, she stated that no such plan is currently under consideration.
